백신 수탁제조 시장 : 백신 유형, 운영 규모, 서비스, 제품 유형, 용도, 최종사용자, 세계 예측(2024-2032년)

Global Vaccine Contract Manufacturing Market will depict 11% CAGR between 2024 and 2032, driven by the rising outsourcing trends. Pharmaceutical companies increasingly outsource vaccine production to reduce costs and focus on core activities. As pharmaceutical companies increasingly focus on core competencies and seek cost efficiencies, they turn to specialized contract manufacturers to handle vaccine production. Outsourcing allows companies to leverage advanced technologies and expertise without investing in costly infrastructure. This trend is driven by the need for scalability, flexibility, and accelerated time-to-market for new vaccines.

For instance, in May 2024, Sanofi, a leading global pharmaceutical company, announced a major investment exceeding €1 billion ($1.08 billion) to expand bioproduction capacity at three sites in France. This investment is part of a broader €3.5 billion program aimed at reducing France's and the EU's reliance on external manufacturing sources. The initiative seeks to enhance supply chain security and resilience, aligning with the EU's health sovereignty concept. This concept, which gained prominence after the COVID-19 pandemic, focuses on strengthening pharmaceutical systems, manufacturing capacities for vaccines and medical products, and improving threat detection and response mechanisms.

In addition, contract manufacturers offer regulatory compliance and quality assurance, further boosting their appeal in the expanding vaccine market.

The overall vaccine contract manufacturing industry is categorized based on vaccine type, scale of operation, service, product type, application, end-user, and region.

The inactivated vaccine contract manufacturing market will drive commendable gains over 2024-2032, propelled by the need for reliable and safe vaccines against various infectious diseases. Inactivated vaccines, which use killed pathogens to stimulate immune responses, are crucial for preventing diseases where live attenuated vaccines are not suitable. Advances in production technology, coupled with rising global health concerns and outbreaks, drive the need for specialized manufacturing. Additionally, regulatory requirements for high-quality, consistent vaccine production further boost the demand for inactivated vaccine contract services.

The clinical segment will capture a substantial market share by 2032. The demand for vaccine contract manufacturing at a clinical scale is stimulated by the need for efficient and scalable production during vaccine development. As clinical trials progress, pharmaceutical companies require specialized manufacturing facilities to produce vaccines in large quantities for testing and evaluation. Contract manufacturers offer the necessary expertise, technology, and flexibility to handle varying scales of production while ensuring compliance with regulatory standards. Additionally, outsourcing these operations helps streamline development timelines and reduces costs, enhancing overall project efficiency.

Europe vaccine contract manufacturing market will grow substantially over 2024-2032 due to stringent regulatory standards that necessitate specialized production capabilities. Increased investment in biopharmaceutical infrastructure and advancements in manufacturing technologies also play a role. Europe's focus on reducing dependence on non-EU production and enhancing supply chain resilience, particularly post-pandemic, drives demand. Additionally, growing public and private sector collaborations, alongside the need for scalable production solutions, further boost the region's contract manufacturing market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for vaccines
    • 3.2.1.2 Increasing adoption of outsourcing services
    • 3.2.1.3 Technological advancements in vaccine technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Increasing cost of vaccines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Attenuated
• 5.3 Inactivated
• 5.4 Subunit-based
• 5.5 Toxoid-based
• 5.6 DNA-based

Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Commercial
• 6.3 Clinical
• 6.4 Preclinical

Chapter 7 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Fill-finish
• 7.3 Bulk vaccines

Chapter 8 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Combination vaccine
• 8.3 Single vaccine

Chapter 9 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Human
• 9.3 Veterinary

Chapter 10 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Pharmaceutical & biotechnology companies
• 10.3 Academic and research institutes

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Ajinomoto Co., Inc.
• 12.2 Bavarian Nordic A/S
• 12.3 Catalent, Inc
• 12.4 Charles River Laboratories International Inc.
• 12.5 Curia Global, Inc.
• 12.6 Cytovance Biologics (Hepalink)
• 12.7 Emergent BioSolutions Inc.
• 12.8 Fujifilm Holdings Corporation
• 12.9 Goodwin Biotechnology Inc.
• 12.10 Gedeon Richter (Richter-Helm BioLogics)
• 12.11 ICON PLC
• 12.12 IDT Biologika GmbH
• 12.13 Lonza Group AG
• 12.14 Recipharm AB
• 12.15 Syngene International Limited